🔎 Trials Near Me

Home › Cancer (all types) › NCT06697600

A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers

Recruiting

Who can join

Ages 60 and older · All sexes

Full eligibility criteria
Patients

Inclusion criteria:

* Age ≥60 years (from date of consent, confirmed on electronic medical records)
* A new diagnosis of AML

  * Diagnosis can be based on the International Consensus Classification or World Health Organization
  * Myeloid sarcoma is allowed
  * AML with central nervous system involvement is allowed
* Cancer-directed treatment has not started

  * Treatment to temporarily decrease white blood cells is acceptable; these may include hydroxyurea, leukapheresis, or cytarabine
  * Intrathecal chemotherapy is acceptable
* The patient's oncologist has been or will be enrolled on the study
* English or Spanish-speaking
* Patients without a caregiver will still be eligible to participate in the study Exclusion criteria
* A diagnosis of acute promyelocytic leukemia
* Patients with psychiatric or cognitive conditions which the treating oncologist believes prohibits informed consent or compliance with study procedures
* Prior cancer-directed treatment for AML

Caregivers

Inclusion criteria:

* Selected by the patient when asked if there is a "family member, partner, friend or caregiver \[age 18 or older\] with whom you discuss or who can be helpful in healthrelated matters."
* Caregiver may be paid/professional or informal caregiver
* Able to provide informed consent
* English or Spanish-speaking

Oncologists

Inclusion criteria:

• Oncologists caring for patients with AML Exclusion criteria

About the study

This is a multicenter randomized controlled trial that assesses the efficacy of a decisional intervention \[University of Rochester-Geriatric Oncology assessment for Acute myeloid Leukemia (UR-GOAL)\] compared to an attention control.

What is being tested

Sponsor: University of Rochester · Participants: 1,020 · Started: Jul 11, 2025

Contact the study team

Official record on ClinicalTrials.gov — NCT06697600

Locations in the U.S.

AlabamaUniversity of Alabama at Birmingham, Division of Hematology and Oncology, Birmingham
New YorkUniversity of Rochester Medical Center, Rochester
North CarolinaUniversity of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill
Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Section of Hematology/Oncology, Winston-Salem

Conditions

From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.